Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;61(8):1343-1356.
doi: 10.1111/apt.70007. Epub 2025 Jan 31.

Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder

Chia-Chih Kuo  1 , Chun-Hsien Li  2 , Min-Hsiang Chuang  1 , Po-Yu Huang  1 , Hsing-Tao Kuo  1   3 , Chih-Cheng Lai  3   4
Affiliations

Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder

Chia-Chih Kuo et al. Aliment Pharmacol Ther. 2025 Apr.

Abstract

Background and aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes in patients with alcohol use disorder (AUD) remains unclear. We investigated the association between GLP-1RAs and the development and progression of alcohol-related liver disease (ArLD) in patients with AUD.

Methods: Using the TriNetX Research Network, we conducted two retrospective cohort studies comparing GLP-1RAs versus dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with type 2 diabetes. The first cohort included patients with AUD but without ArLD (n = 7132 after propensity score matching), while the second comprised patients with established ArLD (n = 1896 after matching). Primary outcomes were incident ArLD in the AUD cohort and hepatic decompensation in the ArLD cohort.

Results: In the AUD cohort (median follow-up: 63.2 months), GLP-1RA users showed significantly lower risks of developing ArLD compared to DPP-4i users (incidence rate: 6.0 vs. 8.7 per 1000 person-years; HR: 0.62, 95% CI: 0.44-0.87, p = 0.006). GLP-1RAs were also associated with reduced risks of all-cause mortality (HR: 0.53, p < 0.001). In the ArLD cohort (median follow-up: 28.2 months), GLP-1RA users demonstrated lower risks of hepatic decompensation (incidence rate: 39.5 vs. 51.4 per 1000 person-years; HR: 0.66, 95% CI: 0.51-0.85, p = 0.001) and all-cause mortality (HR: 0.53, p < 0.001) compared to DPP-4i users.

Conclusions: GLP-1RAs were associated with reduced risks of developing and progressing ArLD in patients with AUD, suggesting potential therapeutic benefits in this population.

Keywords: alcohol use disorder; alcohol‐related liver disease; glucagon‐like peptide‐1 receptor agonists; mortality; real‐world evidence.

PubMed Disclaimer

References

    1. J. P. Connor, P. S. Haber, and W. D. Hall, “Alcohol Use Disorders,” Lancet 387, no. 10022 (2016): 988–998.
    1. H. Y. Choi, D. R. Balter, and L. Y. Haque, “Epidemiology and Health Care Burden of Alcohol Use Disorder,” Clinics in Liver Disease 28, no. 4 (2024): 577–588.
    1. Substance Abuse and Mental Health Services Administration, “Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health,” accessed October 12, 2024, https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022‐ns....
    1. A. F. Carvalho, M. Heilig, A. Perez, C. Probst, and J. Rehm, “Alcohol Use Disorders,” Lancet (London, England) 394, no. 10200 (2019): 781–792.
    1. J. Rehm, A. V. Samokhvalov, and K. D. Shield, “Global Burden of Alcoholic Liver Diseases,” Journal of Hepatology 59, no. 1 (2013): 160–168.

Substances

LinkOut - more resources